

Minority Participants Sought for Clinical Trials

BY NANCY WALSH
New York Bureau

NEW YORK — Racial disparities in access to health care will disappear only when adequate and representative samples of minorities participate in clinical trials, Winston Price, M.D., said at the annual meeting of the National Medical Association.

That disparities in delivery of health care exist is not in question. The Institute of Medicine report "Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare" revealed the extent of the problem, showing that disparities remain even after adjustment for factors such as insurance coverage and socioeconomic status.

But a widespread mistrust of the U.S. health care system among minorities—not least because of past abuses such as the Tuskegee Syphilis Study, in which blacks went untreated for many years despite the



Programs that are successful tend to be well entrenched in the community.

DR. EDWARDS

availability of effective therapy— has led to an unwillingness among African Americans to participate in the clinical trials that might directly benefit their own health.

An increasing understanding of genetic differences and racial differences in response to medications now makes it imperative that minorities be included and their needs addressed in the drug development process, said Dr. Price of the State University of New York Health Science Center, Brooklyn.

The experience with BiDil, a fixed-dose combination of isosorbide dinitrate and hydralazine approved specifically for the treatment of heart failure in black patients, shows it can be done (July 2005, page 1).

"You had 1,050 African Americans who enrolled in the study, and the attrition rate was zero," Dr. Price, who is also president of the NMA, said in a press briefing. "Every single one stayed with that study until completion. The drug was approved by the Food and Drug Administration on June 23, not because it was the right thing to do but because it was pure science and evidence based. All we're asking for is parity."

Other model programs also are demonstrating that blacks can be recruited successfully, Christopher L. Edwards, Ph.D., said at the briefing.

Programs that are successful tend to be well entrenched in the community; they have significant outreach and education and strong, ongoing relationships with local organizations such as churches and fraternities, Dr. Edwards said.

They do not pressure potential study participants, but rather provide information and allow patients to process the in-

formation at home and respond to the investigators when they are ready, he said.

Successful investigators are available to the community not only when recruiting; they are able to articulate the tangible benefits of participation, not only for patients themselves but also for future generations. Dr. Edwards' program in the department of psychiatry at Duke University Medical Center, Durham, N.C., is an example.

"We make ourselves available for inter-

views on television, religious radio, and pop radio. In one creative marketing plan, we placed advertisements for one of our genetic studies on the side of 20 city buses, and have seen a significant number of patients responding," he said.

The overall strategy of information dissemination is to go where the patients are, and not to rely on them to come to us, he said. "With the bus advertisements, the demographic we were recruiting was reliant on public transportation," he added. And

the advertisements provided phone numbers, not e-mail addresses or Web sites because these would not be helpful for a population that doesn't own computers.


In the Duke program, the relevant stakeholders are at the table when recruiting programs are being designed. "If we are recruiting college students, we had students who sat on review panels and advisory boards to give us guidance as to what they would respond to, how, and in what setting," Dr. Edwards said. ■



Rheumatoid arthritis (RA) is a complex autoimmune disease that involves many cell types and multiple signaling mechanisms.^{1,3}

- 1 Activated T cells orchestrate RA immunopathology including destructive downstream events.¹
- 2 Activated T cells initiate and perpetuate RA immunopathology by triggering macrophages and B cells. These cells release cytokines like TNF- α , autoantibodies, and other inflammatory mediators.¹
- 3 The downstream cascade initiated by T cells continues as chondrocytes, osteoclasts, and fibroblast-like cells are activated.¹
- 4 These downstream cells directly cause joint damage and inflammation.¹

APC
The role of co-stimulation in T-cell activation



T-cell activation requires 2 signals. The first signal is recognition of the presented antigen; the second is a co-stimulatory signal. There are multiple co-stimulatory pathways. Selectively targeting one pathway could potentially leave other pathways largely intact.⁴

Bristol-Myers Squibb is actively investigating strategies for the treatment of RA. Like you, we want to seize the moment and seek potentially new rational therapeutic approaches to RA.

References:

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med*. 2001;344:907-916.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. *Nature*. 2003;423:356-361.
3. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. *Nat Rev Drug Discov*. 2003;2:473-488.
4. Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. *Curr Opin Rheumatol*. 2004;16:212-217.